Viral Vectors, Vaccines — A New Era Of Collaborative Design
January 18, 2022
Tags:
Andreas Neubert, Ph.D., Former Chief Science Officer at IDT Biologika, discusses how viral vectors are relatively new to the industry but their value has become more apparent as pharmaceutical technologies and capabilities have evolved.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
.svg)
